News
Public · Published
Stifel maintains Buy rating on ORIC Pharmaceuticals, $18 price target
Stifel maintained a Buy rating on ORIC Pharmaceuticals stock with an $18.00 price target. That target implies 36.7% upside from the October 23 close of $13.17.
Published:
Updated:
What happened
Stifel maintained a Buy rating on ORIC Pharmaceuticals stock with an $18.00 price target. That target implies 36.7% upside from the October 23 close of $13.17.
Confirmed
Global impact / market context
The maintained Buy rating signals continued analyst confidence in ORIC's drug pipeline. The 36.7% implied upside may support investor interest, while the cited clinical data and reduced trial concerns give a rationale for holding or adding the stock.
Analyst inference
The note frames ORIC against competitors in lung cancer and prostate cancer treatment. Encouraging enozertinib data and reduced concerns around the MEVPRO-1 trial may improve perceptions of ORIC's probability of success.
Analyst inference
What to watch
- ORIC's upcoming Phase 3 trial for enozertinib, supported by 84% overall response rate and central nervous system activity in Phase 1b data, is a key event. Confirmed
- Watch whether Stifel's $18.00 price target and Buy rating stay unchanged after new clinical or regulatory updates. Proposed
- Investor positioning may shift if the MEVPRO-1 trial for rinzimetostat progresses, since reduced concerns were cited as justifying the Buy rating. Analyst inference
Evidence
- Original source link unavailable